3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
3
Diabetes Mellitus
2
Vomiting
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Premature Birth
1
Pre-Eclampsia
1
Polycystic Ovary Syndrome
1
Parathyroid Neoplasms
1
Neoplasms
1
Medulloblastoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Leiomyosarcoma
1
Hyperparathyroidism, Primary
1
Hot Flashes
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Erectile Dysfunction
1
Cognitive Dysfunction
1
Carcinoma, Renal Cell
1
Interventions
Imatinib Mesylate
10
Peripheral Blood Stem Cell Transplantation
8
Hydroxyurea
7
Interferon-alpha
6
Cytarabine
6
Radiotherapy
4
Filgrastim
4
Dasatinib
4
Cyclosporine
4
Cyclophosphamide
4
Busulfan
4
nilotinib
3
Methotrexate
3
Idarubicin
3
Early Intervention, Educational
3
olverembatinib
2
liposomal amphotericin B
2
Therapeutics
2
Psychiatric Rehabilitation
2
Mycophenolic Acid
2
Etoposide
2
Cyclosporins
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
sargramostim
1
ponatinib
1
peginterferon alfa-2b
1
fludarabine phosphate
1
bosutinib
1
asciminib
1
Whole-Body Irradiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid, Chronic-Phase
×
Tablets
×
Clear all
NCT01827930
2020-12-31
MIM
Institut Bergonié
Phase 3
Terminated
68 enrolled
13 charts